Investor Relations

Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.

Corporate Presentation June 2026

June 2, 2026

Corporate Presentation

Open Document

Download Document

Events & Presentations

Press Releases

SEC Filings

FAQs

Press Releases

Events

15 minutes delay | Source: LSEG

Price

% change